Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

Editorial summary Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. Unfortunately, very little is known regarding the mechanisms of resistance to such...

Full description

Bibliographic Details

Published in:	Genome Medicine
Main Authors:	Jake S. O’Donnell, Mark J. Smyth, Michele W. L. Teng
Format:	Article
Language:	English
Published:	BMC 2016-10-01
Subjects:	Immune Checkpoint Programme Death Ligand Effective Therapeutic Option Immunosuppressive Tumor Microenvironment Functional Exhaustion
Online Access:	http://link.springer.com/article/10.1186/s13073-016-0365-1